Stockscreener 앱 받기
79.91
2.25%
1.76
시간 외 거래:
79.83
-0.08
-0.10%
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighStill a Buy? - MarketBeat
BridgeBio Pharma stock hits all-time high at 79.88 USD - Investing.com
BridgeBio Pharma, Inc. $BBIO Shares Sold by Emerald Advisers LLC - MarketBeat
How BridgeBio’s (BBIO) Convertible Notes and Attruby Uptake Have Changed Its Investment Story - simplywall.st
BridgeBio Pharma Issues New Convertible Notes and Repurchases Stock - TipRanks
Bridgebio Pharma Inc Issues $632.5 Million Convertible Senior Notes Due 2033 - TradingView — Track All Markets
Avoiding Lag: Real-Time Signals in (BBIO) Movement - Stock Traders Daily
Wells Fargo Raises Price Target on BBIO, Maintains Overweight Ra - GuruFocus
Wells Fargo & Company Raises BridgeBio Pharma (NASDAQ:BBIO) Price Target to $88.00 - MarketBeat
Analysts remain positive on BridgeBio Pharma, Inc. (BBIO) after strong 2025 results - MSN
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results - Yahoo Finance
Mizuho Markets Americas LLC Has $7.29 Million Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio prices $550 million convertible notes at 0.75% interest rate By Investing.com - Investing.com Nigeria
Latham & Watkins Advises on BridgeBio Pharma’s US$550 Million Convertible Senior Notes Offering - Latham & Watkins LLP
BridgeBio Pharma (BBIO) stock edges up after $550 million convertible notes pricing — what investors watch next - TechStock²
BridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Lobbying Update: $60,000 of BRIDGEBIO PHARMA lobbying was just disclosed - Quiver Quantitative
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected - Intellectia AI
BridgeBio Pharma prices $550M convertible bond offering - MSN
BridgeBio Pharma Prices $550 Million Convertible Notes Offering - Intellectia AI
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
BridgeBio Pharma prices $550 million convertible notes offering By Investing.com - Investing.com Canada
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio Pharma Prices $550 Mln Of 0.75% Convertible Senior Notes Due 2033 - Nasdaq
BridgeBio prices $550 million convertible notes at 0.75% interest rate - Investing.com
BridgeBio Pharma, Inc. Announces Pricing of $550 Million Convertible Senior Notes to Enhance Capital Structure and Extend Debt Maturity - Quiver Quantitative
BridgeBio Prices Offering of $550 Million Convertible - GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap DownHere's What Happened - MarketBeat
BridgeBio’s US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO - Yahoo Finance
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress - Yahoo Finance
BridgeBio plans $550 million convertible notes offering to refinance debt By Investing.com - Investing.com Nigeria
BridgeBio plans $550M convertible notes offering due 2033 - MSN
BridgeBio plans $550 million convertible notes offering to refinance debt - Investing.com
BridgeBio Pharma, Inc. Announces Private Offering of $550 Million Convertible Senior Notes to Strengthen Balance Sheet and Extend Debt Maturity - Quiver Quantitative
BridgeBio Pharma Plans Offering of Senior Notes due 2033 - marketscreener.com
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - The Manila Times
BridgeBio continues long term debt management strategy and announces proposed offering of convertible senior notes - marketscreener.com
Biotech BridgeBio reworks $550M in new notes and cash for buybacks - Stock Titan
Ideas Watch: What is the PEG ratio of BridgeBio Pharma IncPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
BridgeBio Pharma (BBIO) Gets a Buy from Raymond James - The Globe and Mail
BridgeBio Pharma stock hits all-time high at 78.69 USD By Investing.com - Investing.com Nigeria
Aug Reactions: Is BridgeBio Pharma Inc stock a value trapJuly 2025 Catalysts & Long-Term Growth Plans - baoquankhu1.vn
Will BridgeBio Pharma Inc stock deliver strong dividend growth2025 Sector Review & Breakout Confirmation Alerts - moha.gov.vn
Evercore ISI Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighShould You Buy? - MarketBeat
BridgeBio Pharma stock hits all-time high at 78.69 USD - Investing.com
Nisa Investment Advisors LLC Grows Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio reports $362.4 million in 2025 Attruby revenue By Investing.com - Investing.com Nigeria
BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat
BridgeBio Pharma CEO Kumar sells $6m in BBIO stock By Investing.com - Investing.com Nigeria
BridgeBio Pharma CEO Kumar sells $6m in BBIO stock - Investing.com
BridgeBio Showcases Attruby Growth and Pipeline Progress - TipRanks
BridgeBio stock maintains Buy rating at TD Cowen on strong Attruby sales - Investing.com Canada
0.46%
0.83%
자본화:
|
볼륨(24시간):